Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-KIR (1-7F9)
Anti-KIR · 1 trial · 1 indication
The maximum tolerated dose (MTD) is the highest dose level below the maximum administered dose (MAD) where none or 1 out of 6 subjects have a DLT.
| Name | Type | Description |
|---|---|---|
| Anti-KIR (1-7F9) | DRUG | human monoclonal antibody |
Inclusion Criteria: 1. Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) 2. Bone marrow plasmacytosis \> 10% (as determined by bone marrow aspirate) or plasmacytoma ...
Top 20 of 25 competitors
Anti-KIR is an investigational therapy that was studied in patients with multiple myeloma, a cancer of plasma cells in the bone marrow. It was evaluated in a single Phase 1 dose-escalation trial in adults with multiple myeloma in the United States. It is not an approved treatment.
Anti-KIR is being developed by Innate Pharma S.A., a biopharmaceutical company whose shares trade under the ticker IPHA. Innate Pharma sponsored the Phase 1 study of Anti-KIR (1-7F9) in multiple myeloma.
Anti-KIR is in Phase 1 clinical development. One Phase 1 trial has been conducted, and it is listed as completed. The study enrolled 32 participants and was an open-label, dose-escalation safety and tolerability trial. Anti-KIR has not been approved by the FDA.
Anti-KIR was studied in the Phase 1 trial NCT00552396, titled an open-label, dose-escalation safety and tolerability trial assessing Anti-KIR (1-7F9) in subjects with multiple myeloma. The trial enrolled 32 adults aged 18 years and older in the United States and is completed.
Yes. Anti-KIR (1-7F9) is an alternative name for Anti-KIR, the same investigational agent developed by Innate Pharma S.A. Both names refer to the compound studied in the Phase 1 multiple myeloma trial NCT00552396.